{
    "clinical_study": {
        "@rank": "112703", 
        "arm_group": [
            {
                "arm_group_label": "Eptifibatide Pre PCI", 
                "description": "Receive eptifibatide pre PCI"
            }, 
            {
                "arm_group_label": "Eptifibatide during PCI", 
                "description": "Receive eptifibatide during PCI"
            }, 
            {
                "arm_group_label": "No Eptifibatide", 
                "description": "Receive no eptifibatide"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this observational study is to evaluate the in hospital and 6 month outcomes of\n      the use of Glycoprotein IIb/IIIa inhibitor eptifibatide as adjunctive therapy in patients\n      undergoing primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction\n      in a large tertiary referral center.\n\n      It is hypothesized that Glycoprotein IIb/IIIa inhibitor use during primary Percutaneous\n      Coronary Intervention for ST-elevation myocardial infarction/ acute myocardial infarction is\n      superior to unfractionated heparin alone or bivalirudin alone. Additionally, after\n      propensity matching this superiority remains."
        }, 
        "brief_title": "Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?", 
        "condition": [
            "ST-elevation Myocardial Infarction", 
            "Acute Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a retrospective, observational, data analysis of approximately 800 patients who\n      underwent primary Percutaneous Coronary Intervention at our institution since September\n      2000. Patients will have either received eptifibatide pre-or during Percutaneous Coronary\n      Intervention or have received no eptifibatide. Patients who received a thrombolytic prior to\n      Percutaneous Coronary Intervention will be excluded.\n\n      This analysis is estimated to take 1-2 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Underwent Percutaneous Coronary Intervention at Washington Hospital Center   since\n             September 2000\n\n          -  Either received eptifibatide pre-or during PCI or have received no eptifibatide.\n\n        Exclusion Criteria:\n\n          -  Patients who received a thrombolytic prior to Percutaneous Coronary Intervention."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who underwent primary Percutaneous Coronary Intervention at Washington Hospital\n        Center since September 2000 and received eptifibatide pre-or during PCI or have received\n        no eptifibatide."
            }
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991366", 
            "org_study_id": "Integrilin Stemi"
        }, 
        "intervention_browse": {
            "mesh_term": "Eptifibatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Major adverse microvascular integrity", 
            "all cause mortality", 
            "Q Wave MI"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "email": "ron.waksman@medstar.net", 
                "last_name": "Ron Waksman, MD", 
                "phone": "202-877-5975"
            }, 
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20010"
                }, 
                "name": "Washington Hospital Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?", 
        "overall_contact": {
            "email": "ron.waksman@medstar.net", 
            "last_name": "Ron Waksman, MD", 
            "phone": "202-877-5975"
        }, 
        "overall_official": {
            "affiliation": "Medstar Research Institute", 
            "last_name": "Ron Waksman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "6-month rates of all-cause mortality and the composite of all-cause mortality or Q-wave myocardial infarction.", 
            "measure": "All-cause mortality and composite or Q-wave myocardial infarction", 
            "safety_issue": "No", 
            "time_frame": "Chart review 6 months after PCI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991366"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Thrombolysis In Myocardial Infarction (TIMI) major bleeding during hospital stay.", 
            "measure": "TIMI major bleeding", 
            "safety_issue": "No", 
            "time_frame": "During hospital stay; average stay is less than 48 hours"
        }, 
        "source": "Medstar Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medstar Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}